Monitoring and Management of Fibrodysplasia Ossificans Progressiva: Current Perspectives

References

• Baujat G, Choquet R, Bouée S, et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet J Rare Dis. 2017;12(1):123. doi:10.1186/s13023-017-0674-5
   PubMed Web of Science ®Google Scholar
• Morales-Piga A, Bachiller-Corral J, Trujillo-Tiebas MJ, et al. Fibrodysplasia ossificans progressiva in Spain: epidemiological, clinical, and genetic aspects. Bone. 2012;51(4):748–755. doi:10.1016/j.bone.2012.07.002
   PubMed Web of Science ®Google Scholar
• Pignolo RJ, Hsiao EC, Baujat G, Lapidus D, Sherman A, Kaplan FS. Prevalence of Fibrodysplasia Ossificans Progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization. Orphanet J Rare Dis. 2021;16(1):350. doi:10.1186/s13023-021-01983-2
   PubMed Web of Science ®Google Scholar
• Nakashima Y, Haga N, Kitoh H, et al. Deformity of the great toe in fibrodysplasia ossificans progressiva. J Orthop Sci. 2010;15(6):804–809. doi:10.1007/s00776-010-1542-5
   PubMed Web of Science ®Google Scholar
• Schroeder HW Jr, Zasloff M. The hand and foot malformations in fibrodysplasia ossificans progressiva. Johns Hopkins Med J. 1980;147(2):73–78.
   PubMedGoogle Scholar
• Bauer AH, Bonham J, Gutierrez L, Hsiao EC, Motamedi D. Fibrodysplasia ossificans progressiva: a current review of imaging findings. Skeletal Radiol. 2018;47(8):1043–1050. doi:10.1007/s00256-018-2889-5
   PubMed Web of Science ®Google Scholar
• Hasegawa S, Victoria T, Kayserili H, et al. Characteristic calcaneal ossification: an additional early radiographic finding in infants with fibrodysplasia ossificans progressiva. Pediatr Radiol. 2016;46(11):1568–1572. doi:10.1007/s00247-016-3662-3
   PubMed Web of Science ®Google Scholar
• Pignolo RJ, Bedford-Gay C, Liljesthröm M, et al. The natural history of flare-ups in Fibrodysplasia Ossificans Progressiva (FOP): a comprehensive global assessment. J Bone Miner Res. 2016;31(3):650–656. doi:10.1002/jbmr.2728
   PubMed Web of Science ®Google Scholar
• Pignolo RJ, Baujat G, Brown MA, et al. Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes. Orphanet J Rare Dis. 2019;14(1):98. doi:10.1186/s13023-019-1068-7
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang K, Song L, et al. The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases. Bone. 2013;57(2):386–391. doi:10.1016/j.bone.2013.09.002
   PubMed Web of Science ®Google Scholar
• Kitterman JA, Kantanie S, Rocke DM, Kaplan FS. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics. 2005;116(5):e654–e661. doi:10.1542/peds.2005-0469
   PubMed Web of Science ®Google Scholar
• Levy C, Berner TF, Sandhu PS, McCarty B, Denniston NL. Mobility challenges and solutions for fibrodysplasia ossificans progressiva. Arch Phys Med Rehabil. 1999;80(10):1349–1353. doi:10.1016/S0003-9993(99)90043-6
   PubMed Web of Science ®Google Scholar
• Kaplan FS, Zasloff MA, Kitterman JA, Shore EM, Hong CC, Rocke DM. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am. 2010;92(3):686. doi:10.2106/JBJS.I.00705
   PubMed Web of Science ®Google Scholar
• Botman E, Smilde BJ, Hoebink M, et al. Deterioration of pulmonary function: an early complication in Fibrodysplasia Ossificans Progressiva. Bone Rep. 2021;14:100758. doi:10.1016/j.bonr.2021.100758
   PubMedGoogle Scholar
• Connor J, Evans C, Evans D. Cardiopulmonary function in fibrodysplasia ossificans progressiva. Thorax. 1981;36(6):419–423. doi:10.1136/thx.36.6.419
   PubMed Web of Science ®Google Scholar
• Kaplan FS, Glaser DL. Thoracic insufficiency syndrome in patients with fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab. 2005;3(3):213–216. doi:10.1385/BMM:3:3-4:213
   Google Scholar
• Kou S, De Cunto C, Baujat G, et al. Patients with ACVR1R206H mutations have an increased prevalence of cardiac conduction abnormalities on electrocardiogram in a natural history study of Fibrodysplasia Ossificans Progressiva. Orphanet J Rare Dis. 2020;15(1):193. doi:10.1186/s13023-020-01465-x
   PubMed Web of Science ®Google Scholar
• Kussmaul WG, Esmail AN, Sagar Y, Ross J, Gregory S, Kaplan FS. Pulmonary and cardiac function in advanced fibrodysplasia ossificans progressiva. Clin Orthop Relat Res. 1998;346:104–109. doi:10.1097/00003086-199801000-00015
   Google Scholar
• Hatsell SJ, Idone V, Wolken DMA, et al. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci Transl Med. 2015;7(303):303ra137–303ra137. doi:10.1126/scitranslmed.aac4358
   PubMed Web of Science ®Google Scholar
• Kaplan FS, Xu M, Seemann P, et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat. 2009;30(3):379–390. doi:10.1002/humu.20868
   PubMedGoogle Scholar
• Song G-A, Kim H-J, Woo K-M, et al. Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva. J Biol Chem. 2010;285(29):22542–22553. doi:10.1074/jbc.M109.094557
   PubMed Web of Science ®Google Scholar
• de Ruiter RD, Smilde BJ, Pals G, et al. Fibrodysplasia Ossificans Progressiva: what have we achieved and where are we now? Follow-up to the 2015 Lorentz Workshop. Front Endocrinol. 2021;12:732728. doi:10.3389/fendo.2021.732728
   PubMed Web of Science ®Google Scholar
• Kaplan FS, Sawyer JR, Connors S, et al. Urinary basic fibroblast growth factor: a biochemical marker for preosseous fibroproliferative lesions in patients who have Fibrodysplasia Ossificans Progressiva. Clin Orthop Relat Res. 1998;346:59–65. doi:10.1097/00003086-199801000-00010
   Google Scholar
• Barruet E, Morales BM, Cain CJ, et al. NF-κB/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification. JCI Insight. 2018;3:22. doi:10.1172/jci.insight.122958
   Web of Science ®Google Scholar
• Kitoh H, Achiwa M, Kaneko H, et al. Perhexiline maleate in the treatment of fibrodysplasia ossificans progressiva: an open-labeled clinical trial. Orphanet J Rare Dis. 2013;8:163. doi:10.1186/1750-1172-8-163
   PubMed Web of Science ®Google Scholar
• Kaplan FS, Al Mukaddam M, Pignolo RJ. A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP). Bone. 2017;101:123–128. doi:10.1016/j.bone.2017.04.015
   PubMed Web of Science ®Google Scholar
• Warner SE, Kaplan FS, Pignolo RJ, et al. Whole-body computed tomography versus dual energy X‑ray absorptiometry for assessing heterotopic ossification in Fibrodysplasia Ossificans Progressiva. Calcif Tissue Int. 2021;109(6):615–625. doi:10.1007/s00223-021-00877-6
   PubMed Web of Science ®Google Scholar
• Eekhoff EMW, Botman E, Coen Netelenbos J, et al. [18F]NaF PET/CT scan as an early marker of heterotopic ossification in fibrodysplasia ossificans progressiva. Bone. 2018;109:143–146. doi:10.1016/j.bone.2017.08.012
   PubMed Web of Science ®Google Scholar
• Eekhoff EMW, Micha D, Forouzanfar T, et al. Collaboration around rare bone diseases leads to the unique organizational incentive of the Amsterdam Bone Center. Front Endocrinol. 2020;11:481. doi:10.3389/fendo.2020.00481
   PubMed Web of Science ®Google Scholar
• Kaplan F, Mukaddam M, Baujat G, et al. The medical management of Fibrodysplasia Ossificans Progressiva: current treatment considerations. Clin Proc Intl Clin Consort FOP. 2019;1:1–111.
   Google Scholar
• Lanchoney TF, Cohen RB, Rocke DM, Zasloff MA, Kaplan FS. Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva. J Pediatr. 1995;126(5 Pt 1):762–764. doi:10.1016/s0022-3476(95)70408-6
   PubMed Web of Science ®Google Scholar
• Kou S, Kile S, Kambampati SS, et al. Social and clinical impact of COVID-19 on patients with Fibrodysplasia Ossificans Progressiva. Res Sq. 2021. doi:10.21203/rs.3.rs-885603/v1
   PubMedGoogle Scholar
• Botman E, Treurniet S, Lubbers WD, et al. When limb surgery has become the only life-saving therapy in FOP: a case report and systematic review of the literature. Front Endocrinol. 2020;11:570. doi:10.3389/fendo.2020.00570
   PubMed Web of Science ®Google Scholar
• Eekhoff EMW, Netelenbos JC, de Graaf P, et al. Flare-up after maxillofacial surgery in a patient with Fibrodysplasia Ossificans Progressiva: an [(18)F]-NaF PET/CT study and a systematic review. JBMR Plus. 2018;2(1):55–58. doi:10.1002/jbm4.10008
   PubMedGoogle Scholar
• Tumolo M, Moscatelli A, Silvestri G. Anaesthetic management of a child with fibrodysplasia ossificans progressiva. Br J Anaesth. 2006;97(5):701–703. doi:10.1093/bja/ael251
   PubMed Web of Science ®Google Scholar
• Liu J-X, Hu R, Sun Y, Jiang H. General anesthesia in fibrodysplasia ossificans progressive: a case report and clinical review. Int J Clin Exp Med. 2014;7(5):1474.
   PubMed Web of Science ®Google Scholar
• Schober P, Krage R, Thöne D, Loer SA, Schwarte LA. Ultrasound-guided ankle block in stone man disease, fibrodysplasia ossificans progressiva. Anesth Analg. 2009;109(3):988–990. doi:10.1213/ane.0b013e3181ac1093
   PubMed Web of Science ®Google Scholar
• Stark WH, Krechel SW, Eggers G Jr. Anesthesia in ‘stone man’: myositis ossif icans progressiva. J Clin Anesth. 1990;2(5):332–335. doi:10.1016/0952-8180(90)90080-M
   PubMedGoogle Scholar
• Maxwell WA, Halushka PV, Miller RL, Spicer SS, Westphal MC, Penny LD. Elevated prostaglandin production in culture cells from a patient with fibrodysplasia ossificans progressiva. Prostaglandins. 1978;15(1):123–129. doi:10.1016/S0090-6980(78)80010-0
   PubMed Web of Science ®Google Scholar
• Convente MR, Chakkalakal SA, Yang E, et al. Depletion of mast cells and macrophages impairs heterotopic ossification in an Acvr1R206H mouse model of fibrodysplasia ossificans progressiva. J Bone Miner Res. 2018;33(2):269–282. doi:10.1002/jbmr.3304
   PubMed Web of Science ®Google Scholar
• Green JR. Antitumor effects of bisphosphonates. Cancer. 2003;97(3 Suppl):840–847. doi:10.1002/cncr.11128
   PubMed Web of Science ®Google Scholar
• Kaplan FS, Andolina JR, Adamson PC, et al. Early clinical observations on the use of imatinib mesylate in FOP: a report of seven cases. Bone. 2018;109:276–280. doi:10.1016/j.bone.2017.07.019
   PubMed Web of Science ®Google Scholar
• Glaser DL, Kaplan FS. Treatment considerations for the management of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab. 2005;3(3):243–250. doi:10.1385/BMM:3:
   Google Scholar
• Nakahara Y, Kitoh H, Nakashima Y, Toguchida J, Haga N. Longitudinal study of the activities of daily living and quality of life in Japanese patients with fibrodysplasia ossificans progressiva. Disabil Rehabil. 2019;41(6):699–704. doi:10.1080/09638288.2017.1405083
   PubMed Web of Science ®Google Scholar
• Peng K, Cheung K, Lee A, Sieberg C, Borsook D, Upadhyay J. Longitudinal evaluation of pain, flare-up, and emotional health in Fibrodysplasia Ossificans Progressiva: analyses of the international FOP registry. JBMR Plus. 2019;3(8):e10181. doi:10.1002/jbm4.10181
   PubMedGoogle Scholar
• Lees-Shepard JB, Nicholas S-AE, Stoessel SJ, et al. Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity. Elife. 2018;7:e40814. doi:10.7554/eLife.40814
   PubMed Web of Science ®Google Scholar
• Hino K, Zhao C, Horigome K, et al. An mTOR signaling modulator suppressed heterotopic ossification of Fibrodysplasia Ossificans Progressiva. Stem Cell Rep. 2018;11(5):1106–1119. doi:10.1016/j.stemcr.2018.10.007
   PubMed Web of Science ®Google Scholar
• Maekawa H, Kawai S, Nishio M, et al. Prophylactic treatment of rapamycin ameliorates naturally developing and episode -induced heterotopic ossification in mice expressing human mutant ACVR1. Orphanet J Rare Dis. 2020;15(1):122. doi:10.1186/s13023-020-01406-8
   PubMed Web of Science ®Google Scholar
• Williams E, Bagarova J, Kerr G, et al. Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva. JCI Insight. 2021;6(8):e95042. doi:10.1172/jci.insight.95042
   PubMed Web of Science ®Google Scholar
• Sánchez-Duffhues G, Williams E, Benderitter P, et al. Development of macrocycle kinase inhibitors for ALK2 using Fibrodysplasia Ossificans Progressiva-derived endothelial cells. JBMR Plus. 2019;3(11):e10230. doi:10.1002/jbm4.10230
   PubMedGoogle Scholar
• Botman E, Teunissen BP, Raijmakers P, et al. Diagnostic value of magnetic resonance imaging in Fibrodysplasia Ossificans Progressiva. JBMR Plus. 2020;4(6):e10363. doi:10.1002/jbm4.10363
   PubMedGoogle Scholar